Novartis eyes double blockbuster potential for Genmab-developed drug

Sclerosis treatment Kesimpta, which was developed by Genmab, could surpass USD 2bn in revenue in the future, says the company selling the drug, Novartis.
by mikkel aabenhus hemmingsen, translated by daniel pedersen

Sclerosis treatment Kesimpta (ofatumumab) will surpass annual sales of USD 2bn over the coming years, said Novartis, the company marketing the drug, on Thursday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading